US 11230530
Human plasma kallikrein inhibitors
granted A61PA61P1/02A61P1/04
Quick answer
US patent 11230530 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/04, A61P13/02